Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine
Prevalence-based Health and Economic Model of the Bivalent Versus the Quadrivalent Human Papillomavirus (HPV) Vaccine
This study compares the health and economic impact of the bivalent HPV vaccine (HPV-1) and
 the quadrivalent HPV vaccine (HPV-2).
This study uses a prevalence-based model (by using efficacy data from each vaccine's
 respective trials and published cost data for Taiwan) which estimates the differences in
 lesions, genital warts, cervical cancer and costs from a healthcare payer's perspective
 prevented between HPV-1 and HPV-2 vaccines during one year (when all women are vaccinated).
 It also analyses costs from a societal perspective.
Inclusion Criteria:

 -  Female subjects vaccinated with either HPV-1 or HPV-2 vaccines in Taiwan (hypothetical
 group).

 Exclusion Criteria:

 -  Not applicable.